Who are Protalix BioTherapeutics, Inc.'s main suppliers?

Protalix BioTherapeutics, Inc. (PLX) key suppliers include: CHIESI, Nasus Pharma Ltd.. View the full supplier network at chainsifter.com/chain/PLX.

Who are Protalix BioTherapeutics, Inc.'s major customers?

Protalix BioTherapeutics, Inc. (PLX) key customers include: CHIESI, CHIESI-GLOBAL-RARE-DISEASES, FIOCRUZ, Pfizer Inc., Pfizer Inc. and 13 more. View the full customer network at chainsifter.com/chain/PLX.

What sector is Protalix BioTherapeutics, Inc. in?

Protalix BioTherapeutics, Inc. (PLX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Protalix BioTherapeutics, Inc. (PLX) Supply Chain: 23 Verified Relationships

2Suppliers

18Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Protalix BioTherapeutics, Inc. (PLX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

24Total relationships

3Distinct source URLs

10High confidence

0.775Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Protalix BioTherapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CHIESI	CHIESI	92%	Revenues from license and R&D services were as follows... The increase in revenues from license and R&D services for the three months ended March 31, 2026 compared to license and R&D services for the…
NSRX	Nasus Pharma Ltd.	62%	Reciprocal relationship from NSRX graph: Reciprocal relationship from PLX graph: Reciprocal relationship from NSRX graph: for the foreseeable future, and we may never achieve or maintain profitabilit…

Protalix BioTherapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
CHIESI	CHIESI	92%	Revenues from customers include $3,513 thousand from Chiesi (Italy) for Fabry disease in 2026 and $0 thousand in 2025.
CHIESI-GLOBAL-RARE-DISEASES	CHIESI-GLOBAL-RARE-DISEASES	92%	the Company, issued a press release, together with its development and commercialization partner, Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A.
FIOCRUZ	FIOCRUZ	92%	Revenues from customers include $2,454 thousand from Fiocruz (Brazil) for Gaucher disease in 2026 and $3,016 thousand in 2025.
PFE	Pfizer Inc.	92%	Reciprocal relationship from PFE graph: Reciprocal relationship from PLX graph: Reciprocal relationship from PFE graph: Reciprocal relationship from PLX graph: Reciprocal relationship from PFE graph:…
PFE	Pfizer Inc.	92%	Revenues from customers include $1,452 thousand from Pfizer (Ireland) for Gaucher disease in 2026 and $6,979 thousand in 2025.
JNJ	Johnson & Johnson	72%	e Brazilian MoH. The Brazilian MoH clinical treatment guidelines (PCDT) state that BioManguinhos alfataliglicerase is the therapy of choice for newly diagnosed patients. BioManguinhos alfataliglicera…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from PLX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from PLX graph: Reciprocal relationship from JNJ graph:…
LGND	Ligand Pharmaceuticals Incorporated	72%	Reciprocal relationship from LGND graph: Reciprocal relationship from PLX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from PLX graph: Reciprocal relationship from LGND gra…
LGND	Ligand Pharmaceuticals Incorporated	72%	e Brazilian MoH. The Brazilian MoH clinical treatment guidelines (PCDT) state that BioManguinhos alfataliglicerase is the therapy of choice for newly diagnosed patients. BioManguinhos alfataliglicera…
SGMO	Sangamo Therapeutics, Inc.	72%	Reciprocal relationship from SGMO graph: Reciprocal relationship from PLX graph: e Brazilian MoH. The Brazilian MoH clinical treatment guidelines (PCDT) state that BioManguinhos alfataliglicerase is …
SGMO	Sangamo Therapeutics, Inc.	72%	e Brazilian MoH. The Brazilian MoH clinical treatment guidelines (PCDT) state that BioManguinhos alfataliglicerase is the therapy of choice for newly diagnosed patients. BioManguinhos alfataliglicera…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from PLX graph: e Brazilian MoH. The Brazilian MoH clinical treatment guidelines (PCDT) state that BioManguinhos alfataliglicerase is…
SNYNF	Sanofi	72%	e Brazilian MoH. The Brazilian MoH clinical treatment guidelines (PCDT) state that BioManguinhos alfataliglicerase is the therapy of choice for newly diagnosed patients. BioManguinhos alfataliglicera…
CO-LLC	CO-LLC	62%	The increase in revenues from license and R&D services for the three months ended March 31, 2026 compared to license and R&D services for the three months ended March 31, 2025 resulted fr…
IF-PROTALIX-LTD	IF-PROTALIX-LTD	62%	d U.S. and Israeli laws. If Protalix Ltd. is unable to make sufficient distributions or advances to us, or if there are limitations on our ability to receive such distributions or advances, we may no…
RESEARCH-COMMITTEE-PROTALIX-LTD	RESEARCH-COMMITTEE-PROTALIX-LTD	62%	hcare items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients whose income and assets fall below state defined levels and who are…
RESEARCH-LAW-PROTALIX-LTD	RESEARCH-LAW-PROTALIX-LTD	62%	hcare items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients whose income and assets fall below state defined levels and who are…
UNITED-STATES-PROTALIX-LTD	UNITED-STATES-PROTALIX-LTD	62%	MoH. The Brazilian MoH clinical treatment guidelines (PCDT) state that BioManguinhos alfataliglicerase is the therapy of choice for newly diagnosed patients. BioManguinhos alfataliglicerase is curren…

Protalix BioTherapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
PLX-DEBT	Debt stack $912,000	90%	Market cache reports total debt of $912,000.
PLX-DEBT-11818	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
PLX-DEBT-11817	Warrants outstanding: 845000	90%	xbrl warrant detail from xbrl 2024-12-31.

Protalix BioTherapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Protalix BioTherapeutics, Inc..

Protalix BioTherapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
PLX-OWNER-BLACKROCK-INC	BlackRock, Inc.	90%	13F overlay lists BlackRock, Inc. as top holder; 100 tracked holders.

Protalix BioTherapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
AZN	AstraZeneca PLC	100.00	2
CSTE	Caesarstone Ltd.	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2

Protalix BioTherapeutics, Inc. Supply Chain